Jazz Pharmaceuticals' first quarter 2026 earnings showed a strong beat, with earnings per share surging past estimates. Despite this, the company's stock declined, and there are indications of a revenue warning signal. The company's stock has had significant movement over the past year, but its current performance and future outlook are uncertain.